Form 4: Cytokinetics Director Edward M. Kaye Reports Acquisition and Disposal of Common Stock and Acquisition of Stock Options

Director Edward M. Kaye reported acquiring 5,600 shares of Cytokinetics common stock and disposing of 24,917 shares, along with acquiring options to purchase 3,636 shares.

Summary

• On May 15, 2024, Edward M. Kaye, a director of Cytokinetics Inc., reported transactions involving the company's securities.
• Kaye acquired 5,600 shares of common stock at $0 per share.
• Simultaneously, Kaye disposed of 24,917 shares of common stock.
• Kaye also acquired non-qualified stock options to buy 3,636 shares of common stock at an exercise price of $60.50, exercisable from June 17, 2024, and expiring on May 15, 2034.
• Following these transactions, Kaye directly owns 24,917 shares of Cytokinetics common stock and options to purchase 3,636 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it's a standard disclosure of insider trading activity. The acquisition and disposal of shares don't inherently indicate a positive or negative outlook.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.

Key Dates